Physician profile
Peter Siegel
NPI 1952927444
$2,012.09
in general payments reported to CMS, 2019-2025
22 companies · $862 in 2025
The $862 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $161 · 2024: $989 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,012.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $315.32 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $287.97 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $261.83 | 2023-2025 | Qulipta, Ubrelvy |
| Pfizer INC. | $186.23 | 2024-2025 | |
| Lilly USA, LLC | $142.11 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $95.41 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $86.02 | 2024-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.87 | 2024-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $78.04 | 2024-2025 | |
| Abbott Laboratories | $75.70 | 2024 | Freestyle Libre 3 |
| Dexcom, INC. | $70.42 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $69.05 | 2023-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $67.59 | 2024 | Auvelity |
| Amgen INC. | $59.46 | 2023-2025 | Repatha, Otezla, Repatha |
| Vivus LLC | $22.18 | 2025 | Pancreaze |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $21.65 | 2023 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $18.68 | 2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $17.88 | 2024 | Xarelto |
| Teva Pharmaceuticals USA, INC. | $16.54 | 2023 | Ajovy |
| Glaxosmithkline, LLC. | $14.68 | 2024 | Arexvy, Shingrix |
| Idorsia Pharmaceuticals US INC | $12.95 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $11.51 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Siegel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.